Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications.
ACS Medicinal Chemistry Letters December 12, 2024 DOI: 10.1021/acsmedchemlett.4c00521 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Psychedelics Mental health treatment Pharmaceutical research Drug development |
| Key findings | Recent patents on controlled-release delivery systems, ester analogs, and acetal/ketal derivatives offer novel approaches to enhance the stability, bioavailability, and efficacy of psilocin and related psychedelic compounds. |
Abstract
Psychedelic compounds, particularly psilocybin and psilocin, have shown significant therapeutic potential in treating neurological and psychiatric disorders. However, their bioavailability, rapid metabolism, and stability challenges have limited their clinical use. This Patent Highlight reviews recent innovations in psychedelic drug delivery systems and the development of psilocin analogs aimed at improving their pharmacokinetic and pharmacodynamic profiles. Three patents-focused on controlled-release delivery systems, ester analogs, and acetal/ketal derivatives-present novel approaches to enhancing the stability, bioavailability, and efficacy of psilocin and related compounds. These advancements promise more effective treatments for conditions such as depression, chronic pain, and neurodegenerative diseases.